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to letrozole in patients with estrogen 
receptor-positive hormone-refractory 
metastatic breast cancer progressing 
on letrozole
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Abstract 
Phase II, open‑label study assessing the efficacy and safety of the ErbB family blocker afatinib combined with letrozole 
in estrogen receptor‑positive metastatic breast cancer (MBC) patients who had progressed on letrozole monotherapy. 
Adult females (N = 28) received oral afatinib (50 [n = 7], 40 [n = 13] or 30 [n = 8] mg/day) plus letrozole 2.5 mg/day in 
28‑day cycles until disease progression. Primary endpoint was the progression‑free rate at or after 16 weeks of afatinib. 
At 16 weeks, four patients remained on afatinib without progression; two of these were HER2 negative. Fifteen (54 %) 
patients had a best response of stable disease according to Response Evaluation Criteria in Solid Tumors. Median 
progression‑free survival was 60, 107 and 79 days with 50, 40 and 30 mg/day afatinib, respectively. Diarrhea, asthe‑
nia, rash, mucosal inflammation and nausea were the most frequent adverse events. In this small, exploratory study, 
afatinib combined with letrozole was able to induce disease stabilization in 54 % of hormone‑refractory MBC patients 
previously progressing on letrozole.
Clinical trial registration: NCT00708214
Keywords: Phase II, Afatinib, ErbB Family Blocker, Letrozole, Metastatic breast cancer, Pharmacokinetics
© 2016 Gunzer et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Abnormally activated ErbB Family receptors (EGFR 
[ErbB1], HER2 [ErbB2], ErbB3 and ErbB4) and estrogen 
receptors (ER) are frequently implicated in breast cancer, 
making these potential therapeutic targets (Hurvitz and 
Pietras 2008; Ciardiello and Tortora 2008). Specifically, 
anti-estrogens, aromatase inhibitors (AIs) and selective 
ER modulators have proven effective in the treatment 
of hormone receptor-positive breast cancer; however, a 
major clinical problem limiting the usefulness of endo-
crine therapy is tumor resistance (Schiff et al. 2004; Chu 
and Lu 2008).
Exploration into the complexity of receptor signal-
ing has identified that receptor crosstalk constitutes a 
fundamental mechanism of tumor resistance, and pre-
clinical observations have confirmed that activation of 
ER and ErbB Family receptors, namely EGFR/HER2, on 
the tumor cell surface stimulates multiple intracellular 
signaling cascades, leading to cellular proliferation, sur-
vival and differentiation (Ullrich and Schlessinger 1990; 
Klapper et  al. 2000). Bidirectional crosstalk can lead to 
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cross-activation of these downstream signaling path-
ways, resulting in the development of tumor resistance 
to endocrine therapy (Nicholson et al. 2001; Arpino et al. 
2008; Hurtado et  al. 2008). To overcome such resist-
ance, the combination of an AI with a tyrosine kinase 
inhibitor (TKI) targeting either EGFR or HER2 has been 
explored and has been shown to enhance response and 
progression-free survival (PFS) compared with treatment 
with an AI alone (Johnston et al. 2009; Cristofanilli et al. 
2010). Such findings confirm that combining endocrine 
treatment with an ErbB Family-targeted therapy could be 
an effective strategy in the management of patients with 
primary or acquired hormone-resistant breast cancer 
(Osborne et  al. 2005). Furthermore, restoration of hor-
mone sensitivity via ErbB Family inhibition could pose a 
therapeutic advantage, providing sustained disease con-
trol without the need for chemotherapy.
Afatinib (BIBW 2992) is an orally available, irrevers-
ible ErbB Family Blocker, with a half maximal inhibitory 
concentration of 0.5 nM, 14 and 1 nM for EGFR, HER2 
and ErbB4, respectively (Li et  al. 2008). This compound 
also inhibits ErbB3 transphosphorylation (Li et al. 2008). 
Phase I monotherapy studies in patients with advanced 
solid tumors recommended a continuous dose of afatinib 
50 mg once daily for the phase II setting (Yap et al. 2010; 
Agus et  al. 2006). Afatinib monotherapy (50  mg/day) 
has previously demonstrated clinical activity in heav-
ily pre-treated patients with HER2-positive metastatic 
breast cancer (MBC) who had progressed following tras-
tuzumab treatment, with a median PFS of 15 weeks and 
an overall survival (OS) of 61 weeks (Lin et al. 2012), as 
well as a small proportion of patients with triple-negative 
MBC who had progressed following no more than two 
prior lines of chemotherapy (Schuler et al. 2010). To fur-
ther investigate the potential activity of afatinib in MBC, 
we undertook a phase II exploratory study to assess the 
efficacy, safety and pharmacokinetics of afatinib in com-
bination with letrozole in patients with ER-positive MBC 
who had progressed on letrozole monotherapy.
Patients and methods
Study design
This was a phase II, open-label, single-arm, multi-
center trial of afatinib added to letrozole in patients 
with ER-positive MBC who had progressed on letrozole 
monotherapy. Patients continued to receive letrozole 
monotherapy during the 2-week screening period. The 
primary efficacy endpoint was progression-free rate at 
or after 16 weeks of afatinib treatment. Progression was 
defined as the occurrence of any of the following: new 
bone lesion(s) identified on a bone scan or with magnetic 
resonance imaging (MRI), progression or occurrence 
of new lesion(s) according to the Response Evaluation 
Criteria In Solid Tumors (RECIST) version 1.0 (Therasse 
et al. 2000), an increase in the tumor marker CA 15.3 of 
more than 20 % compared with the baseline value (at two 
consecutive examinations), or disease-related skeletal 
events (pathological or vertebral compression fracture 
not related to trauma; palliative radiotherapy for bone 
pain; prophylactic radiation or surgery for an impending 
fracture; spinal cord compression). Secondary endpoints 
included objective response (complete response [CR] or 
partial response [PR]) based on RECIST, clinical benefit 
(CR or PR or stable disease [SD]) according to RECIST at 
16 and 24 weeks, PFS, OS, time to and duration of objec-
tive response, pharmacokinetics and safety.
The study was conducted between 30 May 2007 and 4 
January 2010 at five sites in France, and was in accord-
ance with the Declaration of Helsinki, the International 
Conference on Harmonization Good Clinical Practice 
Guideline and approved by the French national regula-
tory agency and local ethics committees. All patients 
provided written informed consent prior to study 
participation.
Study population
Eligible females (≥18 years) had histologically confirmed 
stage IIIB or IV ER-positive MBC. Patients had previ-
ously received letrozole and had developed acquired 
resistance, defined as disease progression on letrozole 
following previous response (PR or better, or SD for 
≥24 weeks). Initially, only patients who had not received 
prior chemotherapy for metastatic disease were allowed 
to participate. Following an amendment, up to two lines 
of prior chemotherapy for MBC were permitted. Patients 
with HER2-positive breast cancer could have received 
prior trastuzumab in the adjuvant and metastatic setting. 
HER2 positivity was not a requirement for study entry. 
Further eligibility criteria included: an Eastern Coopera-
tive Oncology Group performance status of 0 or 1; life 
expectancy of ≥6  months; recovery from any grade 3 
(according to National Cancer Institute Common Termi-
nology Criteria for Adverse Events [NCI CTCAE] version 
3.0) adverse events (AEs) from previous treatment; docu-
mented menopause (estradiol level of <11 pg/mL); diag-
nosis of disease progression ≤6 weeks prior to trial entry; 
and adequate bone marrow (absolute neutrophil count 
≥1500/mm3, platelet count ≥100,000/mm3), hepatic 
(aspartate aminotransferase and/or alanine aminotrans-
ferase ≤3× the upper limit of normal) and renal (serum 
creatinine ≤1.5 mg/dL [≤132 μmol/L, SI unit or equiva-
lent]) function. Patients were excluded from the study if 
they had: chronic diarrhea or gastrointestinal (GI) disor-
ders that could interfere with absorption of study treat-
ment; brain metastases; significant cardiovascular disease 
(i.e., uncontrolled hypertension, unstable angina pectoris, 
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history of infarction, congestive heart failure of New York 
Heart Association grade >2) within the past 12 months; 
received chemotherapy, immunotherapy, radiotherapy, 
other EGFR- and/or HER2-inhibiting drugs, or had par-
ticipated in another clinical study within 4 weeks before 
the start of therapy. Treatment with bisphosphonates was 
allowed if the patient had been receiving a stable dose for 
at least 3 months prior to study entry.
Treatment
Patients received oral afatinib once daily at a starting 
dose of 50 mg (which was reduced to 40 mg and then to 
30  mg following protocol amendments) over repeated 
28-day treatment cycles, with 2.5  mg of oral letrozole 
daily until disease progression, withdrawal of consent 
or discontinuation due to AEs. The study medications 
were administered concurrently 1 h prior to food intake. 
The protocol amendments were made as some patients 
receiving afatinib 50 or 40 mg experienced grade 3 cuta-
neous AEs and diarrhea. As a result, the starting dose of 
afatinib was reduced to 40 mg once-daily and then 30 mg 
once-daily for all newly enrolled patients. At each start-
ing dose, dose reduction of afatinib in 10 mg decrements 
(to a minimum of 20 mg) was a pre-specified option for 
patients experiencing certain drug-related AEs. A safety 
analysis was performed when the initial 15 patients had 
completed 1  month of treatment at either 50 or 40  mg 
afatinib. This analysis was supportive of the reduction 
of the afatinib starting dose from 40 to 30  mg per day. 
Concomitant treatments were permitted as clinically 
necessary.
Efficacy assessments
Efficacy was assessed in terms of the progression-free 
rate at or after 16 weeks of treatment. If a patient with-
drew from the study due to clinical deterioration, accord-
ing to the investigator’s judgment, this was considered as 
progressive disease (PD). Target lesions were evaluated 
by clinical detection, computed tomography or MRI at 
screening and at the end of every other 28-day treatment 
cycle.
Safety assessments
Safety was assessed by monitoring the incidence and 
intensity of AEs that patients experienced. AEs were 
graded according to the NCI CTCAE version 3.0.
Pharmacokinetic sampling and data analysis
For quantification of drug plasma concentrations, 5 mL of 
venous blood was collected. Blood samples were drawn 
before and 2 h after letrozole administration on day –14 
and –7 during the first 2 weeks of letrozole monotherapy 
treatment. For quantification of letrozole and afatinib 
plasma concentrations, blood samples were drawn on day 
1 (cycles 1, 3, 4 and 5) before and 2 h after administra-
tion of afatinib and letrozole, and additionally at 1, 2, 4, 
6, 8 and 24 h after drug administration on day 1 of cycle 
4. Afatinib plasma concentrations were determined by a 
validated high performance liquid chromatography-mass 
spectrometry (HPLC–MS/MS) assay at the Department 
of Drug Metabolism and Pharmacokinetics, Boehringer 
Ingelheim Pharma GmbH and Co. KG, Biberach, Ger-
many. Letrozole plasma concentrations were determined 
by a validated HPLC–MS/MS assay at Nuvisan Pharma 
Services GmbH & Co. KG, Neu-Ulm, Germany.
Statistical analyses
The analyses in this trial were descriptive and exploratory. 
A sample size of 30–40 patients was required to provide 
80 % power to detect statistically significant evidence of 
afatinib activity, based on the assumption of an under-
lying true rate of non-progression of 25  % at 16  weeks. 
Sample size was based on a one-sided alpha of 10  %. 
Analysis was completed on the treated set, comprising all 
patients who received at least one dose of afatinib.
Results
Patient population
Of a total of 30 patients screened, 28 entered the trial 
and received at least one dose of afatinib (Fig. 1). Of the 
two patients who did not enter the trial, one patient did 
not have disease progression and for the other, it was not 
possible to perform blood samples. Baseline patient char-
acteristics are shown in Table 1. Most patients (18; 64 %) 
had experienced SD ≥24 weeks as their best response to 
prior letrozole therapy, with six patients (21  %) experi-
encing a PR, three patients (11 %) experiencing a CR and 
one patient (4 %) having SD (16 weeks).
Clinical activity
Progression‑free rate at 16 weeks (primary endpoint)
A total of 28 patients were evaluable for tumor response. 
Twenty patients (71  %) discontinued treatment prior 
to the 16-week endpoint and eight patients completed 
16 weeks of treatment (Fig. 1). Of these, four (14 %) were 
progression free according to the criteria defined for the 
primary endpoint (Table  2). Two of these patients were 
HER2 negative and the HER2 status was unknown for the 
other two.
Of the four who completed 16  weeks of treatment 
but were not progression-free according to the primary 
endpoint definition, two were diagnosed with PD at the 
16-week assessment. One patient, who received 40  mg 
afatinib, was considered progression-free according to 
RECIST criteria, but had elevated CA 15.3 levels. The 
final patient had suspected RECIST progression prior to 
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16 weeks which was not formally documented due to dif-
ficulty of determining on computed tomography.
For those who discontinued the trial due to PD (n = 15; 
Fig. 2), 13 had RECIST progression, one patient had ele-
vated CA 15.3 levels and bone lesion progression and one 
patient had other criteria indicating PD.
Objective response and clinical benefit rate (RECIST)
No patients experienced an objective (complete or par-
tial) tumor response to afatinib plus letrozole treatment. 
Throughout the study, a best response of SD, as deter-
mined by RECIST, was experienced by 15 patients (54 %). 
The incidence of SD was comparable across the afatinib 
starting dose cohorts. Overall, six patients (21 %) experi-
enced clinical benefit at 16 weeks; this included the four 
patients who met the primary endpoint, the patient who 
was progression-free based on RECIST (but had elevated 
CA 15.3 levels) and one patient who had SD at week 16 
but had discontinued treatment. Of these six patients, the 
best response on prior letrozole therapy was SD for five 
and PR for one patient. Four (14 %) of these six patients 
continued to have clinical benefit at 24  weeks. Best 
response to previous letrozole treatment was PR in one 
patient and SD in three patients.
Progression‑free survival and overall survival
According to RECIST criteria, median PFS (25th percen-
tile, 75th percentile) was 60 (51, 274), 107 (65, 116) and 
79 (51, 230) days for patients initially receiving 50, 40 
and 30 mg afatinib, respectively. The longest duration of 
treatment with afatinib and letrozole was 449 days. Dura-
tion of therapy, along with reasons for discontinuation, is 
shown by starting dose of afatinib for all patients (Fig. 2). 
Median OS could not be estimated due to the small num-
ber of patients who died during the trial (three patients 
died during the trial; none of the deaths were considered 
treatment-related).
Safety
All 28 patients experienced AEs considered to be treat-
ment related by the investigator (Table 3). The most fre-
quently reported treatment-related AEs were diarrhea 
(26 patients; 93 %), asthenia and rash (both 16 patients; 
57  %), mucosal inflammation (11 patients; 39  %) and 
nausea (10 patients; 36  %). The most frequently occur-
ring grade ≥3 treatment-related AEs were diarrhea (six 
patients; 22  %), asthenia and rash (five patients each; 
18  %) (Table  3). No treatment-related grade 5 AEs 
occurred, and only one patient who received afatinib 
Patients screened
N = 30
Patients treated
N = 28
Afatinib starting dose 50 mg
n = 7
5 discontinued treatment
 2 progressive disease
 3 AE
 0 other
11 discontinued treatment
 4 progressive disease
 6 AE
 1 other
4 discontinued treatment
 1 progressive disease
 2 AE
 1 other
2 patients not treated
 1 no disease progression
 1 unable to perform blood sample
Completed 16 weeks’ treatment
n = 2
Progression-free at 16 weeks:
n = 2 (protocol-defined criteria)
n = 2 (RECIST criteria)
Progression-free at 16 weeks:
n = 0 (protocol-defined criteria)
n = 1 (RECIST criteria)
Progression-free at 16 weeks:
n = 2 (protocol-defined criteria)
n = 2 (RECIST criteria)
Completed 16 weeks’ treatment
n = 2
Completed 16 weeks’ treatment
n = 4
Afatinib starting dose 40 mg
n = 13
Afatinib starting dose 30 mg
n = 8
Fig. 1 Trial patient disposition
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40  mg and letrozole 2.5  mg experienced a grade 4 AE 
(diarrhea). Fourteen patients (50  %) discontinued trial 
treatment due to treatment-emergent AEs. The most fre-
quent AEs necessitating treatment discontinuation were 
diarrhea (eight patients; 29  %), asthenia (four patients; 
14  %), rash and mucosal inflammation (three patients 
each; 11 %); some patients had more than one AE leading 
to treatment discontinuation.
Six of the seven patients (86  %) who initially received 
50 mg afatinib underwent protocol-specified dose reduc-
tion to 40  mg for a grade 3 AE. For two of these six 
patients the dose was subsequently further reduced to 
30  mg because they experienced another grade 3 AE. 
Eight of 13 patients (62 %) who initially received 40 mg 
afatinib underwent dose reduction to 30 mg. None of the 
eight patients who received the 30  mg afatinib starting 
dose required dose reduction.
The frequency of AEs observed varied across different 
doses of afatinib. A higher than expected rate of grade 3 
GI and skin-related AEs (rash, acne, dermatitis acneiform 
and palmar–plantar erythrodysesthesia) was observed at 
the 50  mg starting dose. However, patients fully recov-
ered with treatment interruption or discontinuation. Fur-
ther analyses suggested dose-related trends for both rash 
and diarrhea. Among the 16 patients (57  %) who expe-
rienced treatment-related rash, those receiving higher 
doses of afatinib were more likely to experience grade 3 
rash and have a faster onset of symptoms (7  days from 
the start of therapy for patients receiving 50 mg or 40 mg 
compared with 8–14 days for patients receiving 30 mg). 
There was a small decrease in the incidence of drug-
related diarrhea with decreasing dose. The first onset 
of treatment-related diarrhea usually occurred within 
7 days after the start of therapy.
Pharmacokinetics
Afatinib
Table  4 shows the geometric mean pharmacokinetic 
parameters of afatinib after multiple administrations of 
afatinib 30  mg or 40  mg in combination with letrozole 
2.5  mg. Inter-subject variability for maximum plasma 
concentration at steady state (Cmax,ss) and area under the 
plasma concentration–time curve at steady state over the 
dosing interval (AUCtau,ss) was moderate for the afatinib 
40 mg dose group and high for the 30 mg dose group. In 
general, the pharmacokinetic data available were sparse, 
and for the 50 mg afatinib dose group there were insuf-
ficient data to perform any descriptive statistics.
Letrozole
Letrozole trough and 2-h post-dose plasma concentra-
tions were comparable for the screening period (with-
out afatinib administration) and the afatinib treatment 
period, indicating that there was no effect of afatinib on 
letrozole exposure (Fig.  3). In line with this, letrozole 
plasma concentrations appeared to be independent of the 
afatinib dose level. Letrozole pharmacokinetic parame-
ters on day 1 of cycle 4 were summarized over all afatinib 
dose groups (geometric mean Cmax,ss was 135  ng/mL 
and geometric mean AUCtau,ss was 2420  ng*h/mL). The 
Table 1 Demographics and  characteristics of  treated 
patients
ECOG Eastern Cooperative Oncology Group, HER2 human epidermal growth 
factor receptor 2
a Unless otherwise specified
b At screening, the ECOG PS for these patients was 0–1; however, their scores 
worsened to 2 prior to the start of treatment
N (%)a
Total number 28 (100)
Sex
 Female 28 (100)
Age (years)
 Mean 62.5
 Median 64
 Range 40–82
Baseline ECOG performance status
 0 16 (57)
 1 8 (29)
 2b 4 (14)
Progesterone receptor positive 20 (71)
Estrogen receptor positive 27 (96)
HER2 status
 HER2 positive 3 (11)
 HER2 negative 20 (71)
 HER2 unknown or missing 5 (18)
Prior therapies
 Chemotherapy 24 (86)
Prior adjuvant or neoadjuvant chemotherapy
 Yes 19 (68)
 No 9 (32)
Number of prior metastatic chemotherapies
 0 18 (64)
 1 9 (32)
 ≥2 1 (4)
Hormone therapy prior to letrozole 28 (100)
Prior adjuvant radiotherapy
 Yes 16 (57)
 No 12 (43)
Number of prior metastatic radiotherapies
 0 16 (57)
 1 7 (25)
 ≥2 7 (18)
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inter-subject variability for the overall pharmacokinetic 
parameters was high.
Discussion
This phase II study evaluated daily afatinib (30, 40 or 
50 mg/day) in combination with letrozole in ER-positive, 
hormone-refractory MBC. The attempt to overcome 
hormone resistance, i.e. resistance to letrozole by the 
addition of the ErbB Family inhibitor afatinib, achieved 
disease stabilization in four patients (14 %) who remained 
on treatment without progression after 16  weeks. Two 
of these patients were HER2-negative. The use of the 
additional criteria for the diagnosis of progression for 
the primary endpoint was felt important at the time of 
this study as bone lesions were deemed non-measur-
able by RECIST version 1.0. Patients with ER-positive 
breast cancer frequently have bone metastases. Upon 
PD during trial treatment, chemotherapy was available 
to patients as an additional option. In order not to with-
hold chemotherapy from these patients, close monitoring 
Table 2 Summary of patients reaching the primary endpoint (progression-free rate at 16 weeks)
CI confidence interval, MRI magnetic resonance imaging, RECIST Response Evaluation Criteria In Solid Tumors
a Progression was defined as the occurrence of one of the following: new bone lesion(s) on bone scan or on MRI; progression or occurrence of new lesion(s) according 
to RECIST; an increase in the tumor marker CA 15.3 of more than 20 % compared with the baseline value (at two consecutive examinations); or disease-related skeletal 
events
Afatinib 50 mg + letrozole 
2.5 mg
Afatinib 40 mg + letrozole 
2.5 mg
Afatinib 30 mg + letrozole 
2.5 mg
All afatinib doses
Number of patients, n (%) 7 (100.0) 13 (100.0) 8 (100.0) 28 (100.0)
Progression‑free rate
(Protocol‑defined criteria)a,  
n (%) [95 % CI]
2 (28.57)
[3.67–70.96]
0 (0.00)
[0.00–24.71]
2 (25.00)
[3.19–65.09]
4 (14.29)
[4.03–32.67]
Progression‑free rate (RECIST 
criteria), n (%) [95 % CI]
2 (28.57)
[3.67–70.96]
1 (7.69)
[0.19–36.03]
2 (25.00)
[3.19–65.09]
5 (17.86)
[6.06–36.89]
0 100 200 300
Treatment exposure (days)
Afatinib 50 mg
Afatinib 40 mg
Afatinib 30 mg
Reason for discontinuation:
*HER2 positive
Progressive disease
Other AE
Other
254
238
115
111
78
52
21
12*
167
118
99
98*
91
89
86
41
41
35
32
7
1
449
281
91*
52
52
32
7
400 500
Fig. 2 Duration of therapy by starting dose of afatinib for patients who discontinued treatment (each bar represents one patient)
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of PD in bone lesions, which was not necessarily cap-
tured by RECIST 1.0, was required. Overall, the ability of 
afatinib, when administered with letrozole, to induce SD 
in around 50 % of patients may indicate the potential for 
reversal of hormone resistance with this agent. Of note, 
the duration of endocrine therapy prior to afatinib treat-
ment in those who did and did not achieve clinical ben-
efit was not available for all patients, so we are unable to 
speculate as to whether indolent disease contributed to 
any treatment effect in this study.
Clinical evidence that crosstalk between the ER and 
ErbB Family receptors constitutes a mechanism for 
resistance to endocrine therapy is continually growing. 
The membrane-bound ER can directly interact with and/
or activate a variety of receptors, including EGFR and 
HER2. HER2 does not have a specific ligand but is able 
Table 3 Treatment-related adverse events by afatinib starting dose and reported as NCI CTCAE grades (patients with at 
least 1 grade ≥3 adverse event; treated set)
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0)
Afatinib 50 mg +  
letrozole 2.5 mg, n = 7
Afatinib 40 mg +  
letrozole 2.5 mg, n = 13
Afatinib 30 mg +  
letrozole 2.5 mg, n = 8
All afatinib doses +  
letrozole 2.5 mg, n = 28
n (%) n (%) n (%) n (%)
All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3 All grades Grade ≥ 3
Patients with any treatment‑related 
adverse event
7 (100.0) 7 (100.0) 13 (100.0) 8 (61.5) 8 (100.0) 4 (50.0) 28 (100.0) 19 (68)
Adverse event
 Diarrhea 7 (100.0) 1 (14.3) 12 (92.3) 4 (30.8) 7 (87.5) 1 (12.5) 26 (92.9) 6 (21.5)
 Rash 5 (71.4) 5 (71.4) 5 (38.5) 0 6 (75.0) 0 16 (57.1) 5 (17.9)
 Asthenia 4 (57.1) 2 (28.6) 7 (53.8) 1 (7.7) 5 (62.5) 2 (25.0) 16 (57.1) 5 (17.9)
 Mucosal inflammation 5 (71.4) 2 (28.6) 4 (30.8) 2 (15.4) 2 (25.0) 0 11 (39.3) 4 (14.3)
 Nausea 3 (42.9) 0 4 (30.8) 0 3 (37.5) 1 (12.5) 10 (35.7) 1 (3.6)
 Acne 5 (71.4) 3 (42.9) 3 (23.1) 1 (7.7) 0 0 8 (28.6) 4 (14.3)
 Dermatitis acneiform 0 0 5 (38.5) 1 (7.7) 1 (12.5) 0 6 (21.4) 1 (3.6)
 Vomiting 1 (14.3) 0 3 (23.1) 1 (7.7) 1 (12.5) 1 (12.5) 5 (17.9) 2 (7.1)
 Paronychia 1 (14.3) 0 1 (7.7) 1 (7.7) 2 (25.0) 0 4 (14.3) 1 (3.6)
 Dehydration 0 0 1 (7.7) 1 (7.7) 1 (12.5) 0 2 (7.1) 1 (3.6)
 Cheilitis 1 (14.3) 0 1 (7.7) 1 (7.7) 0 0 2 (7.1) 1 (3.6)
 Skin toxicity 0 0 1 (7.7) 1 (7.7) 0 0 1 (3.6) 1 (3.6)
 Arthritis bacterial 0 0 1 (7.7) 1 (7.7) 0 0 1 (3.6) 1 (3.6)
 Pneumococcal sepsis 0 0 1 (7.7) 1 (7.7) 0 0 1 (3.6) 1 (3.6)
 Renal failure acute 0 0 1 (7.7) 1 (7.7) 0 0 1 (3.6) 1 (3.6)
Table 4 Summary of afatinib pharmacokinetic parameters after multiple oral administrations of afatinib 40 and 30 mg, 
with letrozole 2.5 mg
AUCtau,ss area under the plasma concentration–time curve at steady state over the dosing interval, Cmax,ss maximum plasma concentration at steady state, Cpre,ss, 57, 
Cpre,ss, 85 pre-dose plasma concentration on day 1 of cycles 3 and 4, respectively, CV coefficient of variation, tmax,ss time to maximum plasma concentration at steady 
state
a Median and range
Pharmacokinetic parameter (unit) Afatinib 40 mg Afatinib 30 mg
N Geometric mean Geometric CV (%) N Geometric mean Geometric CV (%)
AUCtau,ss (ng*h/mL) 4 660 41.3 5 579 62.8
Cmax,ss (ng/mL) 4 43.8 42.0 5 33.9 79.4
Cpre,ss, 57 (ng/mL) 5 21.4 42.3 8 15.8 42.1
Cpre,ss, 85 (ng/mL) 4 16.9 55.7 5 17.3 46.5
tmax,ss (h)
a 4 2 2–4 5 4.00 0.91–7.67
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to dimerize with EGFR or ErbB3 as a result of its open 
conformation (Schiff et  al. 2004). Therapeutic strategies 
focused around combining endocrine therapy with ErbB 
Family inhibitors, to circumvent de novo or acquired 
resistance, are being explored. Phase II trials investigat-
ing gefitinib or erlotinib, two reversible EGFR TKIs, in 
combination with an AI in ER-positive breast cancer 
patients have demonstrated varying levels of clinical 
benefit, including prolonging PFS, using this combined 
approach (Table 5) (Cristofanilli et al. 2010; Mayer et al. 
2006; Osborne et al. 2011; Smith et al. 2007; Mita et al. 
2005). In our phase II trial, among 28 patients evaluable 
for response, six (21  %) experienced clinical benefit at 
16  weeks and median PFS was 60, 107 and 79  days for 
patients receiving 50, 40 and 30 mg afatinib, respectively, 
demonstrating that the combination of afatinib and letro-
zole may warrant further investigation for hormone-
refractory MBC patients.
One limitation of our trial is the relatively small sam-
ple size; however, this included 20 (71 %) HER2-negative 
patients, two of whom remained on treatment without 
progressing at 16  weeks. This observation is of interest 
because letrozole combined with lapatinib, a reversible 
EGFR and HER2 TKI, in the first-line setting failed to 
improve PFS in patients with ER-positive, HER2-negative 
tumors (Johnston et al. 2009; Schwartzberg et al. 2010). 
Importantly, ER-positive HER2-negative MBC patients 
with low ER expression demonstrated a statistically sig-
nificant improvement in PFS when treated with letrozole 
plus lapatinib (Finn et al. 2009). Targeting HER2 with the 
monoclonal antibody trastuzumab and aromatase inhibi-
tors such as anastrozole has also been explored, and 
the mammalian target of rapamycin (mTOR) inhibitor 
everolimus in combination with endocrine therapy repre-
sents another promising therapeutic strategy for ER-pos-
itive MBC (Table  5) (Huober et  al. 2012; Marcom et  al. 
2007; Kaufman et al. 2009; Bachelot et al. 2012; Baselga 
et al. 2012). Understanding tumor biology and the com-
pensatory mechanisms that are responsible for endocrine 
resistance will drive the choice of combination agent to 
provide optimal, synergistic blockade of relevant signal-
ing pathways.
Across all doses of afatinib, the most frequently 
observed AEs were diarrhea, skin-related AEs, mucosal 
inflammation and asthenia. Overall, the side effect pro-
file reported here was in accordance with the side effects 
observed across the phase I dose-finding afatinib mono-
therapy studies in patients with a variety of solid tumors, 
with GI and skin-related AEs most frequently reported 
(Yap et  al. 2010; Eskens et  al. 2008). These are known 
to be the most prominent AEs associated with EGFR 
blockade and are manageable (Mok et  al. 2009; Mitsu-
domi et al. 2010; Frankel and Palmieri 2010; Rosell et al. 
2012). Data from phase I monotherapy studies indicated 
an afatinib dose of 50  mg once daily to be the recom-
mended dose for afatinib development in subsequent 
phase II studies (Yap et al. 2010; Agus et al. 2006; Eskens 
et  al. 2008; Lewis et  al. 2006). Therefore, patients who 
Fig. 3 Individual plasma concentration–time profiles of letrozole after multiple oral administrations of 30, 40 or 50 mg afatinib
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initially entered this phase II trial received a starting dose 
of afatinib 50  mg daily, with the option for dose reduc-
tion following the occurrence of specific grade 3 AEs. 
A notable proportion of patients initially treated with 
afatinib 50  mg in combination with letrozole experi-
enced skin-associated AEs and diarrhea, requiring a dose 
reduction to 40  mg daily. The occurrence of significant 
skin-associated AEs and diarrhea within the 40 mg dose 
cohort also led to a subsequent dose reduction to 30 mg 
daily. The combination of afatinib/letrozole at a dose of 
30/2.5 mg resulted in fewer patients discontinuing treat-
ment due to AEs than patients who received 50 or 40 mg 
afatinib doses. Overall, the combination of afatinib and 
letrozole appeared to result in skin-related AEs occurring 
at greater intensity, when compared with afatinib mono-
therapy. It is worth noting that at the time of this study 
there was little known about the toxicity profile of TKIs 
and their management.
Co-administration of afatinib with letrozole resulted in 
afatinib pharmacokinetic parameters that were compara-
ble to those observed during afatinib monotherapy (Yap 
et al. 2010; Eskens et al. 2008). Letrozole plasma concen-
trations were also comparable with or without afatinib 
administration and were within the ranges previously 
reported in the literature (Pfister et  al. 2001; Dowsett 
1999), indicating that there was no effect of afatinib on 
letrozole exposure. Therefore, this study is a preliminary 
indication that afatinib has no influence on the pharma-
cokinetics of letrozole and vice versa. However, the phar-
macokinetic analysis was limited by the small number of 
patient samples and, as such, firm conclusions could not 
be drawn.
Despite the significant achievements of endocrine 
therapy in patients with breast cancer, only 50  % of all 
ER-positive tumors are initially responsive to anti-estro-
gens (Mouridsen et  al. 2003; Osborne 1998). Further-
more, in the metastatic setting, tumors that are initially 
responsive always become resistant to endocrine treat-
ment. Therefore, an agent that might suppress or delay 
the onset of endocrine resistance by disrupting multiple 
pathways at once and restoring hormone sensitivity may 
spare patients from treatment with aggressive chemo-
therapy. The phase II exploratory observations presented 
here show that the once-daily afatinib 30  mg/letrozole 
2.5 mg combination was able to induce disease stabiliza-
tion in 54 % of hormone-refractory MBC patients previ-
ously progressing on letrozole. This combination may 
warrant further evaluation, particularly in patients with 
ER-positive HER2-negative MBC. An ongoing study 
(NCT02115048) is assessing the efficacy of afatinib plus 
letrozole versus letrozole alone in first-line advanced ER-
positive, HER2-negative postmenopausal breast cancer 
with low ER expression.
Conclusions
In this small exploratory study, combination therapy with 
afatinib and letrozole led to disease stabilization in 54 % 
of patients with advanced hormone-refractory MBC 
who had progressed following letrozole treatment. These 
findings warrant further evaluation to determine the 
potential for overcoming the resistance associated with 
hormone therapy via ErbB Family blockade with afatinib.
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